| Presentation | 2021-12-27 Drug development based on molecular self-assembly Yukio Nagasaki, |
|---|---|
| PDF Download Page |  PDF download Page Link |
| Abstract(in Japanese) | (See Japanese page) |
| Abstract(in English) | At the end of the 19th century, Paul Ehrlich found that methylene blue stains only the nerve endings of rabbits, so he thought, with a suitable choice of molecules, has no effect on healthy parts of the body and is influenced to the disease sites. He called it a "magic bullet" for such drugs. In the 21st century, a molecular-targeted drug was put into practical use, and his idea was realized. By the molecular target drugs, have cancer patients disappeared from the world? The answer is no, in reality, the number of deaths from cancer patients is steadily increasing year by year. In addition to developing further effective molecular-targeted drugs, a new concept of "medicine" is indispensable for reducing patient pain and improving efficacy. The objective of this research is to construct a new modality for the development of novel drugs by a new concept of molecular-assembling medicines following synthetic organic molecules and biomolecular drugs such as antibody drugs and nucleic acid drugs. This concept is based on the observation that self-assembling antioxidants suppressed their adverse effects significantly and accumulate in the inflammation site and effectively eliminate reactive oxygen species (ROS). Our results indicate the possibility that biological functions and therapeutic effects that cannot be obtained with low molecular weight compounds alone can be controlled by organizing small molecules. In recent years, in the field of drug discovery and development, several medicines whose medicinal effects are exerted only by self-assembling have been discovered. By developing our proposed research, we would like to achieve a system that is friendly to patients as a basis for the creation of an innovative drug discovery industry. |
| Keyword(in Japanese) | (See Japanese page) |
| Keyword(in English) | Molecular self-assembling drugs / Antioxidants / Amino acid / Short chain fatty acids / Reactive oxygen species |
| Paper # | OME2021-38 |
| Date of Issue | 2021-12-20 (OME) |
| Conference Information | |
| Committee | OME |
|---|---|
| Conference Date | 2021/12/27(2days) |
| Place (in Japanese) | (See Japanese page) |
| Place (in English) | Okinawaken Seinen Kaikan |
| Topics (in Japanese) | (See Japanese page) |
| Topics (in English) | bio-technology, surface and interfacial phenomena, measurement and observation, electronics, and other researches relating these |
| Chair | Toshiki Yamada(NICT) |
| Vice Chair | Eiji Itoh(Shinshu Univ.) |
| Secretary | Eiji Itoh(Osaka Univ.) |
| Assistant | Yoshiyuki Seike(Aichi Inst. of Tech.) / Akira Baba(Niigata Univ.) |
| Paper Information | |
| Registration To | Technical Committee on Organic Molecular Electronics |
|---|---|
| Language | JPN |
| Title (in Japanese) | (See Japanese page) |
| Sub Title (in Japanese) | (See Japanese page) |
| Title (in English) | Drug development based on molecular self-assembly |
| Sub Title (in English) | |
| Keyword(1) | Molecular self-assembling drugs |
| Keyword(2) | Antioxidants |
| Keyword(3) | Amino acid |
| Keyword(4) | Short chain fatty acids |
| Keyword(5) | Reactive oxygen species |
| 1st Author's Name | Yukio Nagasaki |
| 1st Author's Affiliation | University of Tsukuba(U. Tsukuba) |
| Date | 2021-12-27 |
| Paper # | OME2021-38 |
| Volume (vol) | vol.121 |
| Number (no) | OME-315 |
| Page | pp.pp.9-14(OME), |
| #Pages | 6 |
| Date of Issue | 2021-12-20 (OME) |